Query: stroke

Filtered By:
Source: Heart Rhythm

This page shows you your search results in order of date.

Order by Relevance | Date

Total 156 results found since Jan 2013.

EP News: Clinical
Yasada et  al (N Engl J Med 2019;381:1103, PMID 31475793) conducted a prospective randomized multicenter trial of 2236 patients with atrial fibrillation (AF) who had undergone percutaneous coronary intervention or coronary artery bypass grafting more than 1 year earlier or who had angiographically confirmed coronary artery disease not requiring revascularization. Patients were randomized to monotherapy with rivaroxaban or combination therapy with rivaroxaban plus a single antiplatelet agent. The primary efficacy end point was a composite of stroke, systemic embolism, myocardial infarction, unstable ang ina requiring revas...
Source: Heart Rhythm - October 28, 2019 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research

Impact of atrial fibrillation/flutter on the in-hospital mortality of ischemic stroke patients
Stroke is the second leading cause of death worldwide. Ischemic strokes, which are caused by atrial fibrillation/flutter (AF) may be more devastating than those without AF.
Source: Heart Rhythm - October 4, 2019 Category: Cardiology Authors: Karsten Keller, Lukas Hobohm, Philip Wenzel, Thomas M ünzel, Christine Espinola-Klein, Mir A. Ostad Source Type: research

Pacing in vasovagal syncope: a physiological paradox?
CThe physiological principles underlying pacemaker treatment in patients with vasovagal syncope (VVS) have never been reviewed. Current knowledge suggests that pacing the right heart is unlikely to correct blood pressure (BP) during a vasovagal reaction. In adults, the reason for this is that stroke volume (SV) is dictated by central blood volume (CBV) contained in the cardiopulmonary vessels within the chest (i.e. left ventricular preload). Preceding posture-triggered VVS, there is a significant fall in CBV and therefore in SV and cardiac output (CO) long before the onset of bradycardia.
Source: Heart Rhythm - September 24, 2019 Category: Cardiology Authors: Jelle SY. de Jong, David L. Jardine, Jacques WM. Lenders, Wouter Wieling Source Type: research

Incidence and Causes of In-hospital Outcomes and 30-day Readmissions After Percutaneous Left Atrial Appendage Closure: A United States Nationwide Retrospective Cohort Study Using Claims Data
Percutaneous left atrial appendage closure (p-LAAC) emerged as an option for stroke prevention in atrial fibrillation (AF) patients ’ ineligible for long-term anticoagulation.Real-world data on its in-hospital and 30-day readmission measures are limited.
Source: Heart Rhythm - September 17, 2019 Category: Cardiology Authors: Venkat L.K. Vuddanda, Mohit K. Turagam, Nikita A. Umale, Zubair Shah, Dhanunjaya R. Lakkireddy, Krzysztof Bartus, Finnian R. McCausland, Poonam Velagapudi, Moussa Mansour, E. Kevin Heist Source Type: research

EP News: Allied Professionals
Di Biase et  al (J Am Coll Cardiol 2019;74:1019, PMID 31439209) sought to assess the incidence of thromboembolic (TE) events such as stroke and transient ischemic attack (TIA) in patients with atrial fibrillation (AF) undergoing ablation for AF that included left atrial appendage (LAA) isolation (LAAI). The st udy group comprised all patients who underwent LAAI as part of their ablation strategy and who were without AF 6 months after ablation. All patients were continued on oral anticoagulation (OAC) with either warfarin or direct oral anticoagulant (DOAC) for the first 6 months.
Source: Heart Rhythm - September 16, 2019 Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research

Thromboembolic, Bleeding, and Mortality Risks among Patients with Nonvalvular Atrial Fibrillation Treated with Dual Antiplatelet Therapy versus Oral Anticoagulants: A Population-Based Study
Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel is used for stroke prevention in patients with atrial fibrillation (AF) when patients refuse to use oral anticoagulants (OAC) in clinical practice. However, there are limited clinical data comparing these treatments.
Source: Heart Rhythm - August 1, 2019 Category: Cardiology Authors: Wallis C.Y. Lau, Ian J. Douglas, Ian C.K. Wong, Liam Smeeth, Gregory Y.H. Lip, Wai K. Leung, Chung-Wah Siu, Bernard M.Y. Cheung, Michael T.C. Mok, Esther W. Chan Source Type: research

Left Atrial Appendage Closure Device Implantation in Patients at Very High Risk for Stroke
Little is known about the role of left atrial appendage closure using Watchman ™ device in patients who are at very high risk for stroke.
Source: Heart Rhythm - July 12, 2019 Category: Cardiology Authors: Erika Hutt, Oussama M. Wazni, Simrat Kaur, Walid I. Saliba, Khaldoun G. Tarakji, Samir Kapadia, Jose Aguilera, Amr F. Barakat, Mouin Abdallah, Wael Jaber, Peter Rasmussen, Shazam Hussain, Ken Uchino, Dolora Wisco, Bruce D. Lindsay, Mohamed Kanj, Ayman A. Source Type: research

Stroke and Dementia Risk in Patients with and without Atrial Fibrillation and Carotid Arterial Disease
We sought to understand the risks of stroke, transient ischemic attack(TIA), and dementia in patients with and without atrial fibrillation (AF) and carotid arterial disease (CD), or a combination of both, and determine if therapies for each disease may influence risks. 11,572 patients were included and matched into 4 groups of 2,893 by the presence of AF and CD. CD and AF augment risk of stroke/TIA and dementia in the general population and the coexistence of both diseases is additive in risk. Ablation of AF was associated with lower risk, the magnitude of which was greater in those with CD.
Source: Heart Rhythm - July 9, 2019 Category: Cardiology Authors: T. Jared Bunch, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Kevin G. Graves, Victoria Jacobs, Charles Mallender, Jeffrey S. Osborn, J. Peter Weiss, Heidi T. May Source Type: research

EP News: Clinical
Hohnloser et  al (Circulation 2019;139:2315, PMID 30976787) assessed the safety and efficacy of once-daily edoxaban 60 mg (30 mg in patients indicated for dose reduction) vs vitamin K antagonists (VKAs) in patients with atrial fibrillation undergoing catheter ablation in a multinational, multicenter, random ized, open-label, parallel-group trial. Patients were randomized 2:1 to edoxaban vs VKA. The primary end point was the time to first occurrence of all-cause death, stroke, or major bleeding during the period from the end of the ablation procedure to the end of treatment (90 days).
Source: Heart Rhythm - June 25, 2019 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research

The Heart Rhythm Society/American College of Physicians Atrial Fibrillation Screening and Education Initiative
The prevalence of both atrial fibrillation (AF) and stroke is increasing. Stroke is common in AF and can have devastating consequences, especially when AF is unrecognized, and anticoagulation is not initiated.
Source: Heart Rhythm - April 4, 2019 Category: Cardiology Authors: Lynda E. Rosenfeld, Alpesh Navin Amin, Jonathan C. Hsu, Asa Oxner, Mellanie True Hills, David S. Frankel Source Type: research

Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Due to very high thromboembolic risk, life-long oral anticoagulation is recommended in all hypertrophic cardiomyopathy (HCM) patients with non-valvular atrial fibrillation (NVAF).1-3 We read with great interest the paper by Tsuda et al.4 who rightly emphasized the importance of HCM on thromboembolism in patients with AF.
Source: Heart Rhythm - April 4, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Source Type: research

Author's reply to Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Dr. Joung and colleagues for their interests in our work.1 In our study, patients with non-valvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than NVAF patients without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study of Jung et al.,2 the stroke risk in NVAF with HCM without any other stroke risk factor was greater than that in NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all NVAF patients with HCM should receive anticoagulation.
Source: Heart Rhythm - April 4, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research

To the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
Because of high thromboembolic risk, lifelong oral anticoagulation is recommended in all patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM).1 –3 We read with great interest the article by Tsuda et al,4 who rightly emphasized the importance of HCM in thromboembolism in patients with AF.
Source: Heart Rhythm - April 4, 2019 Category: Cardiology Authors: Boyoung Joung, Gregory Y.H. Lip Tags: Letter to the Editor Source Type: research

Reply to the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Joung et  al for their interest in our work.1 In our study, patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than did patients with NVAF without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study by Jung et  al,2 stroke risk in patients with NVAF with HCM without any other stroke risk factor was higher than that in patients with NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all patients with NVAF with HCM should receive anticoagulation.
Source: Heart Rhythm - April 4, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research

Cryoballoon Pulmonary Vein Ablation and Left Atrial Appendage Closure Combined Procedure: a long term follow up analysis Cryoablation with Concomitant Left Atrial Appendage Closure
combined left atrial appendage closure (LAAC) and cryo-energy pulmonary vein isolation (PVI) procedure has been proven safe and effective in managing stroke in patients with non-valvular atrial fibrillation (AF), although most data refer to procedures performed using radiofrequency (RF) as main energy source.
Source: Heart Rhythm - March 27, 2019 Category: Cardiology Authors: Gaetano Fassini, Alessio Gasperetti, Gianpiero Italiano, Stefania Riva, Massimo Moltrasio, Antonio Dello Russo, Michela Casella, Anna Maltagliati, Fabrizio Tundo, Benedetta Majocchi, Luca Arioli, Ghaliah Al-Mohani, Gianluca Pontone, Mauro Pepi, Claudio To Source Type: research

Cryoballoon pulmonary vein ablation and left atrial appendage closure combined procedure: A long-term follow-up analysis
The combined left atrial appendage closure (LAAC) and cryoenergy pulmonary vein isolation (PVI) procedure has been proven safe and effective in managing stroke in patients with nonvalvular atrial fibrillation (AF), although most data refer to procedures performed using radiofrequency as the main energy source.
Source: Heart Rhythm - March 27, 2019 Category: Cardiology Authors: Gaetano Fassini, Alessio Gasperetti, Gianpiero Italiano, Stefania Riva, Massimo Moltrasio, Antonio Dello Russo, Michela Casella, Anna Maltagliati, Fabrizio Tundo, Benedetta Majocchi, Luca Arioli, Ghaliah Al-Mohani, Gianluca Pontone, Mauro Pepi, Claudio To Source Type: research

Atrial Ca2+/calmodulin-dependent protein kinase II: A druggable master switch of atrial fibrillation-associated atrial remodeling?
Atrial fibrillation (AF) is the most common arrhythmia and is associated with increased morbidity and mortality, with heart failure (HF) and thromboembolism including stroke being the major consequences.1 Thus, stroke prevention with oral anticoagulants is crucial, but highly challenging, for AF management in many patients.2,3 Although our understanding of the underlying molecular mechanisms promoting AF increased substantially over the years, contemporary approaches using drugs are only moderately effective and have substantial side effects, including proarrhythmia.
Source: Heart Rhythm - February 5, 2019 Category: Cardiology Authors: Dobromir Dobrev Tags: Editorial Commentary Source Type: research

Left Atrial Appendage Closure Device Implantation in Patients with Atrial Fibrillation and Prior Intracranial Hemorrhage “No Man Left Behind”
Several LAA closure devices have been developed for patients with atrial fibrillation (AF) seeking an alternative to long-term oral anticoagulation (OAC). The PROTECT AF trial was the first multicenter randomized controlled trial (RCT) comparing LAA closure device vs. OAC with Warfarin. Primary safety events were statistically more frequent in the device group (7.4% vs. 4.4%). At a mean follow up of 3.8 years LAA closure device showed superiority for the primary efficacy endpoint (i.e., composite of stroke, cardiovascular death and systemic embolism), with a 34% relative risk reduction in total mortality1-3 However, with t...
Source: Heart Rhythm - January 14, 2019 Category: Cardiology Authors: Luigi Di Biase, Jorge Romero Source Type: research

CHA2DS2-VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation
High CHA2DS2-VASc scores in atrial fibrillation (AF) patients are generally associated with increased risks of stroke and dementia. At lower CHA2DS2-VASc scores, there remains an unquantifiable cranial injury risk, necessitating an improved risk assessment method within these lower-risk groups.
Source: Heart Rhythm - January 1, 2019 Category: Cardiology Authors: Kevin G. Graves, Heidi T. May, Victoria Jacobs, Kirk U. Knowlton, Joseph B. Muhlestein, Donald L. Lappe, Jeffrey L. Anderson, Benjamin D. Horne, T. Jared Bunch Tags: Featured Article Source Type: research

Refining the prediction of stroke in atrial fibrillation: An elusive endeavor
Atrial fibrillation (AF), the most common sustained arrhythmia, is responsible for>20% of all strokes.1 AF-associated strokes are more severe, causing significantly greater long-term disability, accounting for greater resource utilization, and resulting in significantly higher mortality compared to non-AF strokes.2 –4 Oral anticoagulants (OACs) are the standard of care for the prevention of AF-associated stroke and systemic thromboembolism. To date, OACs are the only therapeutic intervention that has been consistently and definitively shown to improve survival in the AF population.
Source: Heart Rhythm - December 18, 2018 Category: Cardiology Authors: Jason G. Andrade, Laurent Macle Tags: Editorial Commentary Source Type: research

Refining the Prediction of Stroke in Atrial Fibrillation. An elusive endeavor
Atrial fibrillation (AF), the most common sustained arrhythmia, is responsible for>20% of all strokes.1 AF-associated strokes are more severe, causing significantly greater long-term disability, accounting for greater resource utilization, and result in significantly higher mortality when compared to non-AF strokes.2-4 Oral anticoagulants (OACs) are the standard of care for the prevention of AF-associated stroke and systemic thromboembolism. To date OACs are the only therapeutic intervention that has been consistently and definitively shown to improve survival in the AF population.
Source: Heart Rhythm - December 18, 2018 Category: Cardiology Authors: Jason G. Andrade, Laurent Macle Source Type: research

A New Model to Predict Ischemic Stroke in Patients with Atrial Fibrillation Using Warfarin or Direct Oral Anticoagulants
Stroke risk stratification scores (e.g., CHA2DS2-VASc) are used to tailor therapeutic recommendations for patients with atrial fibrillation (AF) in different risk groups.
Source: Heart Rhythm - December 11, 2018 Category: Cardiology Authors: J ’Neka S. Claxton, Richard F. MacLehose, Pamela L. Lutsey, Faye L. Norby, Lin Y. Chen, Wesley T. O’Neal, Alanna M. Chamberlain, Lindsay G.S Bengtson, Alvaro Alonso Source Type: research

Atrial Fibrillation Occurring During Head-up Tilt Test: Once detected, AF should be monitored, regardless of how it is detected
Atrial fibrillation (AF) often progresses to more sustained forms and raises the risk of ischemic stroke or sinus node dysfunction (SND). However, there has been no data on the clinical outcomes of AF developed during head-up tilt testing (HUT).
Source: Heart Rhythm - December 4, 2018 Category: Cardiology Authors: Jun Hyung Kim, Sung Ho Lee, Seung-Jung Park, Kyoung Min Park, Young Keun On, June Soo Kim Source Type: research

Stroke in patients with cardiovascular implantable electronic device infection undergoing transvenous lead removal
Stroke can be a devastating complication in patients with cardiovascular implantable electronic device (CIED) infection. Paradoxical septic embolism can occur in the presence of device leads and patent foramen ovale (PFO) via embolic dislodgment during transvenous lead removal (TLR).
Source: Heart Rhythm - October 30, 2018 Category: Cardiology Authors: Justin Z. Lee, Pradyumna Agasthi, Ahmed K. Pasha, Claudia Tarin, Andrew S. Tseng, Nancy N. Diehl, David O. Hodge, Christopher V. DeSimone, Ammar M. Killu, Peter A. Brady, Krishna Kancharla, Fred M. Kusumoto, Komandoor Srivathsan, Michael J. Osborn, Raul E Tags: Featured Article Source Type: research

Seasonal variation in the risk of ischemic stroke in patients with atrial fibrillation: A nationwide cohort study
Several cardiovascular diseases exhibit seasonal variations, but data about cold temperature and risk of ischemic stroke in patients with atrial fibrillation (AF) are limited.
Source: Heart Rhythm - July 2, 2018 Category: Cardiology Authors: Jo-Nan Liao, Tze-Fan Chao, Chia-Jen Liu, Su-Jung Chen, Chung-Lieh Hung, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Fa-Po Chung, Tzeng-Ji Chen, Gregory Y.H. Lip, Shih-Ann Chen Source Type: research

Race and stroke in an atrial fibrillation inception cohort: Findings from the Penn Atrial Fibrillation Free study
Stroke may be the initial manifestation of atrial fibrillation (AF). Limited studies, however, have evaluated racial differences in stroke before the diagnosis of AF.
Source: Heart Rhythm - February 19, 2018 Category: Cardiology Authors: Parin J. Patel, Ronit Katz, Yuliya Borovskiy, Anthony Killian, Joshua M. Levine, Nelson W. McNaughton, David Callans, Gregory Supple, Sanjay Dixit, Andrew E. Epstein, Francis E. Marchlinski, Rajat Deo Tags: Clinical Source Type: research

Irregularity and lack of p-waves in short tachycardia episodes predict atrial fibrillation and ischemic stroke
Atrial fibrillation (AF) is defined as an irregular supraventricular tachycardia (SVT) without p-waves, with a duration>30s. It is not known whether AF characteristics in shorter SVT episodes predict AF and stroke.
Source: Heart Rhythm - February 12, 2018 Category: Cardiology Authors: Linda S.B. Johnson, Anders P. Persson, Per Wollmer, Steen Juul-M öller, Tord Juhlin, Gunnar Engström Source Type: research

Irregularity and lack of p waves in short tachycardia episodes predict atrial fibrillation and ischemic stroke
Atrial fibrillation (AF) is defined as an irregular supraventricular tachycardia (SVT) without p waves, with duration>30 seconds. Whether AF characteristics during short SVT episodes predict AF and stroke is not known.
Source: Heart Rhythm - February 12, 2018 Category: Cardiology Authors: Linda S.B. Johnson, Anders P. Persson, Per Wollmer, Steen Juul-M öller, Tord Juhlin, Gunnar Engström Source Type: research

Atrial fibrillation ablation, stroke and mortality. Evaluating the effects of therapy in the era of big data
Atrial fibrillation (AF) is associated with an increased stroke and mortality risk. The logical extension of this is that if AF is controlled or eliminated then patient outcomes with respect to stroke and mortality should improve. The AFFIRM trial comparing rate and rhythm control strategies unfortunately did not demonstrate an improvement in either of these endpoints in the rhythm control population (1). An interesting sub-analysis of the AFFIRM trial did however indicate that patients who were in sinus rhythm more often at the time of their follow-up had a reduced mortality (2).
Source: Heart Rhythm - February 10, 2017 Category: Cardiology Authors: Steven J. Kalbfleisch Source Type: research

Atrial fibrillation ablation, stroke, and mortality: Evaluating the effects of therapy in the era of big data
Atrial fibrillation (AF) is associated with an increased stroke and mortality risk. The logical extension of this is that if AF is controlled or eliminated then patient outcomes with respect to stroke and mortality should improve. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial1 comparing rate and rhythm control strategies unfortunately did not demonstrate an improvement in either of these end points in the rhythm control population. An interesting subanalysis of the AFFIRM trial2 did, however, indicate that patients who were in sinus rhythm more often at the time of their follow-up had a reduced mortality.
Source: Heart Rhythm - February 10, 2017 Category: Cardiology Authors: Steven J. Kalbfleisch Tags: Editorial Commentary Source Type: research

Warfarin Use and the Risk of Mortality, Stroke, and Bleeding in Hemodialysis Patients with Atrial Fibrillation
The optimal management of stroke prophylaxis in hemodialysis patients with atrial fibrillation is controversial.
Source: Heart Rhythm - February 6, 2017 Category: Cardiology Authors: Brandon Kai, Yuliya Bogorad, Leigh-Ann N. Nguyen, Su-Jau Yang, Wansu Chen, Hillard T. Spencer, Albert Y.-J. Shen, Ming-Sum Lee Source Type: research

Benefits of non –vitamin K antagonist oral anticoagulants in patients with atrial fibrillation go beyond stroke prevention
The last decade has produced a large body of robust randomized controlled trial (RCT) data investigating the use of non –vitamin K antagonist oral anticoagulants (NOACs) in nonvalvular atrial fibrillation (AF).1–4 Compared with warfarin, dabigatran and apixaban have been found to reduce the combined outcome of stroke and systemic embolism. In addition, apixaban and edoxaban significantly reduce major bleeding. Fu rthermore, a pooled meta-analysis has demonstrated superior efficacy and overall safety of the NOACs.
Source: Heart Rhythm - January 16, 2017 Category: Cardiology Authors: Jay A. Montgomery, Gregory F. Michaud Tags: Editorial Commentary Source Type: research

Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies
A direct comparison of the efficacy and safety profiles of left atrial appendage occlusion (LAAO) devices and novel oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation is warranted but currently unavailable.
Source: Heart Rhythm - December 24, 2015 Category: Cardiology Authors: Xin Li, Song-Nan Wen, Song-Nan Li, Rong Bai, Nian Liu, Li Feng, Yan-Fei Ruan, Xin Du, Jian-Zeng Dong, Chang-Sheng Ma Source Type: research

Over One Year Efficacy and Safety of Left Atrial Appendage Occlusion Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Observational Studies
Direct comparison of the efficacy and safety profile between left atrial appendage occlusion (LAAO) devices and novel oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF) is warranted but currently unavailable.
Source: Heart Rhythm - December 24, 2015 Category: Cardiology Authors: Xin Li, Song-Nan Wen, Song-Nan Li, Rong Bai, Nian Liu, Li Feng, Yan-Fei Ruan, Xin Du, Jian-Zeng Dong, Chang-Sheng Ma Source Type: research

Volume and Morphology of Left Atrial Appendage as Determinants of Stroke Subtype in Patients with Atrial Fibrillation
Atrial fibrillation (AF) is a leading cause of stroke, but not all cases of stroke in patients with AF are due to AF.
Source: Heart Rhythm - December 18, 2015 Category: Cardiology Authors: Woo Kyo Jeong, Jin-Ho Choi, Jeong Pyo Son, Suyeon Lee, Mi Ji Lee, Yeon Hyeon Choe, Oh Young Bang Source Type: research

Comparisons of CHADS and CHADS-VASc scores for stroke risk stratification in atrial fibrillation: Which scoring system should be used for Asians?
Both U.S. and European guidelines recommend use of the CHA2DS2-VASc rather than CHADS2 score for stroke risk stratification in atrial fibrillation (AF). However, the CHA2DS2-VASc score has not been proved to be better than CHADS2 score for Asians in a large-scale study.
Source: Heart Rhythm - August 12, 2015 Category: Cardiology Authors: Tze-Fan Chao, Chia-Jen Liu, Ta-Chuan Tuan, Su-Jung Chen, Kang-Ling Wang, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Tzeng-Ji Chen, Chern-En Chiang, Shih-Ann Chen Source Type: research

Comparisons of CHADS2 and CHA2DS2-VASc Scores for Stroke Risk Stratification in Atrial Fibrillation – Which Scoring System should be Used for Asians?
Both American and European guidelines recommended the use of CHA2DS2-VASc score, rather than CHADS2, for stroke risk stratification in atrial fibrillation (AF). However, the CHA2DS2-VASc score has not been proved to be better than CHADS2 for Asians in a large-scale study.
Source: Heart Rhythm - August 12, 2015 Category: Cardiology Authors: Tze-Fan Chao, Chia-Jen Liu, Ta-Chuan Tuan, Su-Jung Chen, Kang-Ling Wang, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Tzeng-Ji Chen, Chern-En Chiang, Shih-Ann Chen Source Type: research

The metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic
The prevalence of atrial fibrillation (AF) and AF-related stroke is set to increase dramatically in coming decades, with developing regions such as Latin America experiencing the greatest impact. These trends are primarily driven by aging populations and by the increasing prevalence of the metabolic syndrome. The metabolic syndrome describes an association between diabetes, hypertension, obesity, and dyslipidemia and an increased risk of cardiovascular disease. It is in large part the result of unbalanced diet and sedentary lifestyle.
Source: Heart Rhythm - June 30, 2015 Category: Cardiology Authors: Reza Hajhosseiny, Gareth K. Matthews, Gregory Y.H. Lip Tags: Contemporary Review Source Type: research

The Metabolic Syndrome, Atrial Fibrillation and Stroke: Tackling An Emerging Epidemic
The prevalence of atrial fibrillation (AF) and AF-related stroke is set to increase dramatically in coming decades, with developing regions such as Latin America experiencing the greatest impact. These trends are primarily driven by aging populations and by the increasing prevalence of metabolic syndrome. Metabolic syndrome describes an association between diabetes, hypertension, obesity, dyslipidaemia and an increased risk of cardiovascular disease. It is in large part the result of unbalanced diet and sedentary lifestyle.
Source: Heart Rhythm - June 30, 2015 Category: Cardiology Authors: Reza Hajhosseiny, Gareth K. Matthews, Gregory YH Lip Tags: CRV Source Type: research

Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic
The prevalence of atrial fibrillation (AF) and AF-related stroke is set to increase dramatically in coming decades, with developing regions such as Latin America experiencing the greatest impact. These trends are primarily driven by aging populations and by the increasing prevalence of the metabolic syndrome. The metabolic syndrome describes an association between diabetes, hypertension, obesity, and dyslipidemia and an increased risk of cardiovascular disease. It is in large part the result of unbalanced diet and sedentary lifestyle.
Source: Heart Rhythm - June 30, 2015 Category: Cardiology Authors: Reza Hajhosseiny, Gareth K. Matthews, Gregory Y.H. Lip Tags: Contemporary Review Source Type: research

HRS/NSA 2014 Survey of Atrial Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement
The prevalence of atrial fibrillation (AF) is substantial and increasing. Stroke is common in AF and can have devastating consequences. Oral anticoagulants are effective in reducing stroke risk, but are underutilized.
Source: Heart Rhythm - May 13, 2015 Category: Cardiology Authors: David S. Frankel, Sarah E. Parker, Lynda E. Rosenfeld, Philip B. Gorelick Source Type: research

Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: a propensity matched study of 24,244 patients
Stroke is the major cause of morbidity and mortality related to atrial fibrillation (AF). Catheter ablation for AF is effective in reducing AF burden, but its impact on long-term stroke risk is unknown.
Source: Heart Rhythm - February 20, 2015 Category: Cardiology Authors: Peter A Noseworthy, Suraj Kapa, Abhishek J Deshmukh, Malini Madhavan, Holly Van Houten, Lindsey R Haas, Siva K Mulpuru, Christopher J McLeod, Samuel J Asirvatham, Paul A Friedman, Nilay D Shah, Douglas L Packer, D. Robert, Patricia E. Kern Source Type: research

Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: A propensity-matched study of 24,244 patients
Stroke is the major cause of morbidity and mortality related to atrial fibrillation (AF). Catheter ablation for AF is effective in reducing AF burden, but its impact on long-term stroke risk is unknown.
Source: Heart Rhythm - February 20, 2015 Category: Cardiology Authors: Peter A. Noseworthy, Suraj Kapa, Abhishek J. Deshmukh, Malini Madhavan, Holly Van Houten, Lindsey R. Haas, Siva K. Mulpuru, Christopher J. McLeod, Samuel J. Asirvatham, Paul A. Friedman, Nilay D. Shah, Douglas L. Packer Source Type: research

Glycated Hemoglobin and Risk of First Episode Stroke in Diabetic Patients with Atrial Fibrillation: A Cohort Study
Diabetes is associated with increased risk of stroke in patients with atrial fibrillation. Whether glycemic control, evaluated by glycated hemoglobin, affects the risk of stroke in diabetic patients with atrial fibrillation remains unknown.
Source: Heart Rhythm - January 19, 2015 Category: Cardiology Authors: W. Saliba, O. Barnett-Griness, M. Elias, G. Rennert Source Type: research

Cryptogenic stroke: Is silent atrial fibrillation the culprit?
Stroke without an identifiable cause is frightening to patients and their families and is frustrating for the caring physician. Approximately 30% of patients with cardiac implanted electronic devices have some evidence of atrial fibrillation (AF), and much of it is silent, asymptomatic, and previously unrecognized.
Source: Heart Rhythm - October 3, 2014 Category: Cardiology Authors: Taya V. Glotzer, Paul D. Ziegler Source Type: research

Admittance to detect alterations in left ventricular stroke volume
Implantable cardioverter-defibrillators monitor intracardiac electrocardiograms (EGMs) to discriminate between ventricular and supraventricular tachycardias. The incidence of inappropriate shocks remains high because of misclassification of the tachycardia in an otherwise hemodynamically stable individual. Coupling EGMs with an assessment of left ventricular (LV) stroke volume (SV) could help in gauging hemodynamics during an arrhythmia and reducing inappropriate shocks.
Source: Heart Rhythm - June 27, 2014 Category: Cardiology Authors: Erik R. Larson, John E. Porterfield, Sandeep Sagar, Juan Marmol-Velez, Manoj Panday, Daniel Escobedo, Joel Michalek, Yongjian Ouyang, Jonathan W. Valvano, John A. Pearce, Marc D. Feldman Source Type: research

Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis
Renal dysfunction is a significant risk factor for ischemic stroke in atrial fibrillation (AF). However, the incidence of ischemic stroke and how to predict its occurrence among AF patients with end-stage renal disease (ESRD) are unclear.
Source: Heart Rhythm - June 18, 2014 Category: Cardiology Authors: Tze-Fan Chao, Chia-Jen Liu, Kang-Ling Wang, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Fa-Po Chung, Jo-Nan Liao, Tzeng-Ji Chen, Gregory Y.H. Lip, Shih-Ann Chen Source Type: research